Here’s a conversation I have more often than you’d think. A VP of Market Access — smart, experienced, absolutely knows what good RWE looks like — tells me they’ve just signed with a new data provider. Third one in four years. “This one’s different,” they say. “Better coverage, much more analysis-ready, GDPR sorted.” Three months later, I hear from them again. You can probably guess how that conversation goes.
Vendor fatigue in the pharma data space is real. And the frustrating part? It’s not because the data doesn’t exist, or because your team isn’t capable. It’s because the vendor evaluation process — the way most organisations actually go about selecting real-world data providers — is structurally set up to produce disappointing outcomes.
So let’s talk about that. Honestly, and without the sales deck.
If you’re past vendor selection and thinking about what good data delivery actually looks like in practice, our earlier post on analysis-ready real-world evidence and healthcare data for pharma covers that ground.
The Vendor Fatigue Problem — and Why It Keeps Happening
The Pan-European RWD vendor landscape has grown dramatically over the last decade. More providers, more overlapping capabilities, more competing claims about coverage and compliance and analytical sophistication. On paper, that’s good for buyers. More competition, more options, better value.
In practice? It’s made the evaluation problem significantly harder.
When a market matures quickly, differentiation narrows. Vendor pitches start converging on the same language — “longitudinal tracking,” “analysis-ready datasets,” “GDPR-compliant anonymisation,” “therapeutic area depth.” After your third or fourth vendor demo in a month, you genuinely struggle to remember which provider said what. The decks look different. The substance, increasingly, doesn’t.
And here’s the thing that doesn’t get said enough: this isn’t accidental. It’s a consequence of how vendor sales processes are designed. They’re optimised to win contracts, not to help you make the right decision. Demos are curated. Sample datasets are pre-selected for relevance. Reference customers are, by definition, the ones who agreed to be references — not the ones who walked away after eighteen frustrating months.
Makady et al., writing in Value in Health, identified inconsistent approaches to evaluating real-world data sources as one of the primary obstacles to HTA acceptance of RWE submissions across European markets.[1] And Garrison et al.’s foundational ISPOR task force report flagged the absence of standardised evaluation criteria for RWD sources as a systemic problem — almost two decades ago.[2] Two decades later, the vendor landscape is ten times more complex. The evaluation process still isn’t keeping up.
So. Why is the landscape this hard to navigate? Three structural reasons.
Coverage claims are almost impossible to verify from the outside
“Coverage across key Continental European markets” could mean almost anything. Comprehensive longitudinal records across France, the Netherlands, Switzerland, and Scandinavia — or partial administrative data from a limited subset of payers in one or two markets. You won’t know which until you’re well into the engagement.
Each national healthcare system in Continental Europe works differently. Payer structures, coding conventions, data governance frameworks — all of it varies by market. A dataset with strong coverage in one country can have genuine gaps in the next. Coverage breadth and therapeutic depth aren’t the same thing either, and vendors rarely volunteer that distinction upfront. The question that actually matters is whether their data covers your specific indication, your target patient population, and the markets relevant to your HTA submissions. That’s a much more granular ask than any top-line figure answers. One reliable proxy for genuine data quality is asking whether the vendor has published or can provide phenotype validation documentation — performance metrics showing how accurately their data supports disease cohort identification for your specific indication.
GDPR compliance claims are even harder to verify
Every provider will tell you they’re GDPR-compliant. Under GDPR Article 9, health data requires either explicit legal basis for processing or — the more defensible position — genuine anonymisation that removes it from GDPR’s scope entirely. The legal and technical distinction between true anonymisation and pseudonymisation matters enormously here. And it’s consistently blurred in vendor materials.
Vendors rarely disclose their anonymisation methodology in detail — understandably, it’s a competitive asset — but that creates a real due diligence gap. You may be licensing datasets that carry more residual re-identification risk than the compliance language implies. National data protection authorities across Continental Europe are increasingly active in enforcement. That risk sits with you, not the vendor.
Analytical capability varies more than the pitch suggests
Some providers offer genuine study design support, domain expertise by therapeutic area, and pre-built analytical environments. Others give you data access and expect your team to handle everything from data engineering to protocol development internally. That difference is enormous — particularly for lean teams without a dedicated RWE function. And you typically don’t discover which type you’ve signed with until three months in, when the “analysis-ready” dataset turns out to need substantial internal processing before it supports the study you actually need.
What Most Pharma Teams Get Wrong (And It’s Not What You’d Expect)
I want to be careful here, because the mistakes I’m about to describe aren’t failures of intelligence or diligence. They’re structural. They’re built into how vendor evaluation typically gets run — and they’ll produce the same outcomes regardless of how smart or experienced your team is, unless the process itself changes.
Evaluating brand reputation instead of fit-for-purpose
The biggest names in pharma data analytics carry serious weight. And that weight drives procurement decisions in ways that aren’t always warranted. A vendor with strong brand recognition in one therapeutic area may have real gaps in the area that matters for your specific program. “Fit-for-purpose” is the operative concept — the RECORD statement on observational routinely-collected health data is explicit that data source appropriateness has to be evaluated against the specific study design and research question, not on generic quality metrics.[3]
Brand is an understandable shortcut when you don’t have the expertise to do the evaluation properly. But it’s also one of the most reliable paths to a disappointing vendor relationship.
Assessing coverage without thinking about study design first
Patient record counts, market coverage percentages, therapeutic area breadth — these are the headline numbers vendors lead with because they’re the easiest to communicate impressively. And they’re almost useless in isolation.
Hernan and Robins established this clearly in their target trial emulation framework: the validity of real-world evidence depends on whether the data source can support the specific causal question being asked — not on its general scale or breadth.[4] A large dataset with poor coverage of your target cohort is less valuable than a smaller, well-structured one that captures the population you actually need. Most vendor comparisons never get to this level of specificity — because requirements haven’t been defined precisely enough to ask the question.
Skipping GDPR due diligence — or doing it superficially
“GDPR-compliant” has become standard vendor boilerplate that communicates almost nothing about actual privacy architecture. The questions that matter — What anonymisation methodology was applied? Can you demonstrate re-identification is not reasonably possible? How is data governance documented and auditable? What are the national GDPR implementation requirements for each market covered? — rarely make it into evaluation processes, because most procurement and analytics teams don’t have the privacy law expertise to ask them confidently.
Vendors, unsurprisingly, don’t volunteer answers to questions they’re not asked.
Entering vendor conversations without defined requirements
Honestly, this is the mistake that enables all the others. If you don’t have a clear, detailed specification of what you need before the first vendor conversation, the vendor’s framing of their capabilities will shape your evaluation criteria. You end up assessing them against their own metrics, not yours.
A rigorous requirements definition — covering therapeutic area, patient population, target markets, study design, analytical requirements, timeline, GDPR compliance standards, and budget — should happen before any vendor conversation begins. Most teams skip it because it requires internal alignment and specialist knowledge they don’t readily have. The cost shows up later.
Treating peer recommendations as independent validation
Peer recommendations are valuable intelligence, but only when the peer’s use case, therapeutic area, internal capabilities, and market focus closely match yours. A recommendation from a colleague at a large pharma company with a mature internal RWE function means something different if you’re a lean biotech team building your evidence strategy for the first time. And recommendations are almost never accompanied by an honest account of what didn’t work.
Understanding which data sources match specific use cases requires deep market knowledge that most companies lack internally — and that peer networks, however trusted, can only partially substitute for.
Why Independent RWE Advisory Changes the Equation
Now here’s the conversation I find most valuable to have with pharma teams before they re-enter the vendor market. For many organisations, engaging an independent RWE advisor before starting vendor evaluation isn’t an additional cost. It’s a risk mitigation strategy — one that typically delivers faster, better-matched, and more cost-effective outcomes than navigating the landscape alone. Let me explain why that’s actually true, not just something an advisory firm would say.
Structural neutrality produces structurally better advice
An independent RWE advisor has no commercial relationship with any data vendor. Their incentive is entirely aligned with helping you find the right match for your specific use case. That structural neutrality changes the quality of advice fundamentally — in the same way that methodological independence changes the credibility of a comparative effectiveness study.
The GRACE principles for observational research, developed by Dreyer et al., establish that independence and transparency are foundational to credible real-world evidence.[5] The same logic applies to vendor evaluation. And most organisations don’t have genuinely independent expertise within their own walls — or the bandwidth to apply it even if they did.
Market knowledge you can’t get any other way
The challenge most pharma companies face isn’t finding real-world data providers. There are plenty of them. It’s determining which combination of capabilities genuinely aligns with their strategic priorities — and what the vendor landscape actually looks like beneath the sales pitch.
That kind of knowledge takes years to develop. It’s not available from vendor materials or peer networks. And it degrades quickly in a market that evolves as fast as the Pan-European RWD space. Kesselheim and Doherty’s 2021 analysis in Health Affairs makes the point well: the gap between available data and fit-for-purpose evidence is a knowledge and methodology problem as much as a data access problem.[6] Bridging it requires expertise that most organisations have to go outside their walls to access.
It’s faster than you think — and cheaper than getting it wrong
This one surprises people. The assumption is that bringing in an advisory firm adds time and cost to vendor selection. In practice, the opposite tends to be true.
Internal vendor evaluation cycles — without specialist support — routinely run four to six months. That’s four to six months of stakeholder management across medical, commercial, legal, IT, and procurement. Multiple parallel vendor conversations creating internal confusion and conflicting recommendations. Evaluation criteria that shift as the process unfolds. And at the end of it, a decision made with imperfect information under deadline pressure.
A structured advisory engagement compresses that timeline considerably. Requirements are defined clearly upfront. The vendor shortlist reflects genuine fit assessment rather than brand recognition. Due diligence is conducted by someone who knows what to look for. And the resulting recommendation carries actual specialist weight.
The advisory cost is, in most cases, substantially lower than one additional month of internal team time on an inefficient procurement process — and orders of magnitude lower than twelve or twenty-four months locked into the wrong vendor relationship.
When it matters most
Not every organisation needs the same level of support. But independent advisory tends to deliver the highest value in a few specific situations: lean pharma and biotech teams without a dedicated RWE or HEOR function; organisations re-entering the vendor market after a disappointing previous engagement; companies facing high-stakes evidence requirements — multi-market HTA submissions, post-approval safety studies, DARWIN EU-linked analyses — where poor data quality has direct regulatory consequences; and teams under compressed timelines where getting the process right the first time is operationally critical.
For teams thinking through patient journey and treatment pathway analysis specifically — where vendor data quality has direct downstream consequences — our post on real-world treatment pathway analysis using aggregated claims data covers the data requirements in detail.
And for a broader view of how RWD and claims analytics capabilities vary across the market, our piece on how data science transforms pharma through RWD and claims analytics is worth a read.
Red Flags Worth Knowing Before Your Next Vendor Conversation
Whether you work with an advisor or go it alone, there are specific warning signs that any sophisticated pharma buyer should recognise. These aren’t hypothetical. They’re patterns that come up repeatedly — and that consistently predict problems downstream.
Vague coverage claims without therapeutic area specificity. “Strong coverage across key European markets” isn’t an answer. Press vendors to demonstrate coverage for your specific indication and target patient population. If the answer stays vague, that tells you something important about the data and about the vendor’s transparency.
No validation documentation. Rigorous datasets come with documented validation methodology — ideally benchmarked against national statistical authorities or published epidemiological estimates. Schneeweiss et al. established that transparent longitudinal data documentation is a basic standard for research-grade datasets.[7] If a vendor can’t provide it clearly, that’s a material data quality concern.
Ambiguous GDPR and anonymisation architecture. The EMA’s DARWIN EU network sets explicit standards for data governance and privacy protection in RWE generation across European markets.[8] If a vendor can’t articulate the distinction between anonymisation and pseudonymisation — and specifically which standard their data meets — that’s a compliance red flag worth taking seriously before you sign anything.
Pressure to commit before evaluation is complete. Sales cycle urgency is normal. Pressure to commit before you’ve reviewed sample data, validated coverage claims, and assessed compliance architecture is a different thing. Vendors with genuinely strong products don’t typically need to rush the process.
Evasiveness about data sourcing. Understanding where the data comes from — which payer systems, administrative databases, or health records contribute — matters for assessing representativeness and potential selection bias. Vendors who cite only “proprietary partnerships” without structural explanation are making independent quality assessment impossible. That’s a problem for scientific validity and GDPR documentation alike.
Vendor Fatigue Is Solvable. It Just Requires a Different Starting Point.
Vendor fatigue isn’t a sign that real-world data is too complex to work with. It’s a sign that the conventional approach to vendor evaluation — unstructured, reactive, without specialist guidance — is poorly suited to a market that’s genuinely sophisticated now.
The pharma teams that consistently make good vendor decisions tend to have a few things in common. They define requirements rigorously before entering the market. They evaluate vendors against their own criteria rather than vendor-supplied benchmarks. They conduct GDPR and data quality due diligence with the expertise to make it meaningful. And they treat vendor selection as the strategic evidence investment it actually is.
Sherman et al. made this point clearly in their foundational NEJM analysis of real-world evidence: the value of RWE isn’t inherent in the data. It’s produced through rigorous methodology, appropriate data selection, and transparent analysis.[9] Getting the vendor decision right is the first step in that chain — and it’s where most organisations currently leave the most value on the table.
The good news is that this is genuinely solvable. Not by becoming experts in every corner of the Pan-European RWD vendor landscape — that’s not a realistic expectation for any internal team. But by recognising that expert advisory exists precisely for this purpose, and that bringing it in early is a strategic choice that pays for itself.
If you’re navigating a vendor evaluation — or expecting one — we’d welcome a conversation. Reach out to discuss your specific evidence requirements and explore how independent RWE advisory can get you from vendor fatigue to vendor confidence — faster, and with a lot less risk.
And if you’re thinking through the data architecture side — what makes a dataset genuinely analysis-ready versus merely accessible — our next post on aggregated and synthetic insurance data picks up exactly there.
Sources & References
- Makady, A., et al. (2017). Policies for use of real-world data in health technology assessment. Value in Health, 20(3), 520–532. https://www.valueinhealthjournal.com
- Garrison, L. P., et al. (2007). Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value in Health, 10(5), 326–335. https://www.valueinhealthjournal.com
- Benchimol, E. I., et al. (2015). The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) statement. PLOS Medicine, 12(10). https://journals.plos.org/plosmedicine
- Hernan, M. A., & Robins, J. M. (2016). Using big data to emulate a target trial when a randomized trial is not available. American Journal of Epidemiology, 183(8), 758–764. https://academic.oup.com/aje
- Dreyer, N. A., et al. (2018). GRACE principles: recognizing high-quality observational studies of comparative effectiveness. American Journal of Managed Care, 16(6), 467–471. https://www.ajmc.com
- Schneeweiss, S., et al. (2019). Graphical depiction of longitudinal study designs in health care databases. Annals of Internal Medicine, 170(6), 398–406. https://www.acpjournals.org
- European Medicines Agency (2023). Data analysis and real-world interrogation network (DARWIN EU). EMA. https://www.ema.europa.eu
- Sherman, R. E., et al. (2016). Real-world evidence — what is it and what can it tell us? New England Journal of Medicine, 375(23), 2293–2297. https://www.nejm.org
- U.S. Food and Drug Administration (2023). Real-world data: assessing electronic health records and medical claims data to support regulatory decision-making for drugs and biological products. FDA Guidance Document. https://www.fda.gov
- Berger, M. L., et al. (2017). Good practices for real-world data studies of treatment and/or comparative effectiveness. European Journal of Epidemiology, 32(11), 945–947. https://pmc.ncbi.nlm.nih.gov/
- ISPOR (2022). Real-world evidence transparency initiative: guiding principles. ISPOR Special Report. https://www.ispor.org
category: https://medddical.com/rwd-medical-real-world-synthetic-data-pharma/